KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Other Gross PP&E Adjustments (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Other Gross PP&E Adjustments data on record, last reported at $989.9 million in Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 54.43% year-over-year to $989.9 million; the TTM value through Dec 2025 reached $989.9 million, down 54.43%, while the annual FY2025 figure was $989.9 million, 54.43% down from the prior year.
  • Other Gross PP&E Adjustments reached $989.9 million in Q4 2025 per VRTX's latest filing, up from -$1.6 billion in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $2.2 billion in Q4 2024 and bottomed at -$1.6 billion in Q3 2025.
  • Average Other Gross PP&E Adjustments over 5 years is -$54.3 million, with a median of -$320.3 million recorded in 2021.
  • Peak YoY movement for Other Gross PP&E Adjustments: grew 17.68% in 2023, then plummeted 349.63% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $1.5 billion in 2021, then rose by 13.4% to $1.7 billion in 2022, then increased by 17.68% to $2.0 billion in 2023, then rose by 8.84% to $2.2 billion in 2024, then plummeted by 54.43% to $989.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were $989.9 million in Q4 2025, -$1.6 billion in Q3 2025, and -$1.3 billion in Q2 2025.